Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Assets Average (2020 - 2025)

Historic Assets Average for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $940.1 million.

  • Apellis Pharmaceuticals' Assets Average rose 408.37% to $940.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $940.1 million, marking a year-over-year increase of 408.37%. This contributed to the annual value of $836.9 million for FY2024, which is 805.93% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Assets Average stood at $940.1 million for Q3 2025, which was up 408.37% from $814.3 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Assets Average's 5-year high stood at $1.1 billion during Q2 2022, with a 5-year trough of $612.8 million in Q3 2021.
  • Its 5-year average for Assets Average is $861.2 million, with a median of $868.2 million in 2024.
  • In the last 5 years, Apellis Pharmaceuticals' Assets Average plummeted by 2519.71% in 2021 and then surged by 5301.8% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Assets Average (Quarter) stood at $703.7 million in 2021, then rose by 16.03% to $816.6 million in 2022, then dropped by 1.6% to $803.5 million in 2023, then grew by 11.2% to $893.5 million in 2024, then rose by 5.22% to $940.1 million in 2025.
  • Its Assets Average was $940.1 million in Q3 2025, compared to $814.3 million in Q2 2025 and $846.2 million in Q1 2025.